Amifampridine
(OYTKINVCDFNREN-UHFFFAOYSA-N)
Structure
- SMILES
- Nc1cnccc1N
- Type(s)
- Approved; Investigational
- ATC code(s)
- N07XX05
- Molecular Formula:
- C5H7N3
- Molecular Weight:
- 109.129
- Log P:
- 1.4084
- Hydrogen Bond Acceptor:
- 3
- Hydrogen Bond Donor:
- 2
- TPSA:
- 64.93
- CAS Number(s):
- 54-96-6
Synonym(s)
1.
Amifampridine
2.
3,4-Diaminopyridine
3.
Amifampridine Phosphate
4.
Firdapse
5.
3,4 Diaminopyridine
External Link(s)
| MeSH | D000077770 |
| PubChem Compound | 5918 |
| BindingDB | 50416493 |
| ChEBI | 135948 |
| CHEMBL | CHEMBL354077 |
| DrugBank | DB11640 |
| DrugCentral | 4336 |
| IUPHAR/BPS Guide to PHARMACOLOGY | 8032 |
| KEGG | dr:D10228 |
| ZINC | 164000 |
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Drug ineffective | FAERS: 7 | US FAERS | |
| 2 | Asthenia | FAERS: 6 | US FAERS | |
| 3 | Headache | FAERS: 5 | US FAERS | |
| 4 | Feeling abnormal | FAERS: 4 | US FAERS | |
| 5 | Nasopharyngitis | FAERS: 4 | US FAERS | |
| 6 | Hypersensitivity | FAERS: 3 | US FAERS | |
| 7 | Malaise | FAERS: 3 | US FAERS | |
| 8 | Urticaria | FAERS: 3 | US FAERS | |
| 9 | Aphasia | FAERS: 2 | US FAERS | |
| 10 | Back Pain | FAERS: 2 | US FAERS | |
| 11 | Dehydration | FAERS: 2 | US FAERS | |
| 12 | Diplopia | FAERS: 2 | US FAERS | |
| 13 | Dizziness | FAERS: 2 | US FAERS | |
| 14 | Dysarthria | FAERS: 2 | US FAERS | |
| 15 | Dyspepsia | FAERS: 2 | US FAERS | |
| 16 | Infection | FAERS: 2 | US FAERS | |
| 17 | Myasthenic Syndrome | FAERS: 2 | US FAERS | |
| 18 | Peripheral swelling | FAERS: 2 | US FAERS | |
| 19 | Product dose omission | FAERS: 2 | US FAERS | |
| 20 | Product substitution issue | FAERS: 2 | US FAERS | |
| 21 | Tachycardia | FAERS: 2 | US FAERS | |
| 22 | Therapeutic product effect decreased | FAERS: 2 | US FAERS | |
| 23 | Therapeutic product effect incomplete | FAERS: 2 | US FAERS | |
| 24 | Therapeutic response delayed | FAERS: 2 | US FAERS | |
| 25 | Anxiety | FAERS: 1 | US FAERS | |
| 26 | Arthralgia | FAERS: 1 | US FAERS | |
| 27 | Cellulitis | FAERS: 1 | US FAERS | |
| 28 | Chest Pain | FAERS: 1 | US FAERS | |
| 29 | Clostridium difficile infection | FAERS: 1 | US FAERS | |
| 30 | Depressed mood | FAERS: 1 | US FAERS | |
| 31 | Fatigue | FAERS: 1 | US FAERS | |
| 32 | Feeling Cold | FAERS: 1 | US FAERS | |
| 33 | Flatulence | FAERS: 1 | US FAERS | |
| 34 | Gait inability | FAERS: 1 | US FAERS | |
| 35 | Hypokinesia | FAERS: 1 | US FAERS | |
| 36 | Inappropriate schedule of product administration | FAERS: 1 | US FAERS | |
| 37 | Inflammation | FAERS: 1 | US FAERS | |
| 38 | Joint injury | FAERS: 1 | US FAERS | |
| 39 | Laryngitis | FAERS: 1 | US FAERS | |
| 40 | Muscle Rigidity | FAERS: 1 | US FAERS | |
| 41 | Musculoskeletal stiffness | FAERS: 1 | US FAERS | |
| 42 | Nausea | FAERS: 1 | US FAERS | |
| 43 | Oropharyngeal pain | FAERS: 1 | US FAERS | |
| 44 | Overdose | FAERS: 1 | US FAERS | |
| 45 | Pain | FAERS: 1 | US FAERS | |
| 46 | Palpitations | FAERS: 1 | US FAERS | |
| 47 | Performance status decreased | FAERS: 1 | US FAERS | |
| 48 | Pneumonia | FAERS: 1 | US FAERS | |
| 49 | Prescribed overdose | FAERS: 1 | US FAERS | |
| 50 | Product quality issue | FAERS: 1 | US FAERS | |
| 51 | Pruritus | FAERS: 1 | US FAERS | |
| 52 | Quality of life decreased | FAERS: 1 | US FAERS | |
| 53 | Restless Legs Syndrome | FAERS: 1 | US FAERS | |
| 54 | Tremor | FAERS: 1 | US FAERS | |
| 55 | Unevaluable event | FAERS: 1 | US FAERS | |
| 56 | Urinary tract infection | FAERS: 1 | US FAERS | |
| 57 | Visual Impairment | FAERS: 1 | US FAERS | |
| 58 | Vomiting | FAERS: 1 | US FAERS | |
| 59 | Weight decreased | FAERS: 1 | US FAERS | |
| 60 | Muscle Weakness | 7570638 | CTD |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120237
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.